{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:02:44Z","timestamp":1791388964073,"version":"4.3.3"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejca.2022.08.012","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T19:08:08Z","timestamp":1663873688000},"page":"236-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer: Primary results from PALOMA-4"],"prefix":"10.1016","volume":"175","author":[{"given":"Binghe","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shude","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuizhi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiun-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virote","family":"Sriuranpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger K.C.","family":"Ngan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee H.","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huadong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejca.2022.08.012_bib1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/jnci\/djz090","article-title":"Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population","volume":"111","author":"Lin","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejca.2022.08.012_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2022.08.012_bib3","series-title":"NCCN clinical Practice guidelines in Oncology (NCCN Guidelines\u00ae) breast cancer version 4.2021","year":"2021"},{"key":"10.1016\/j.ejca.2022.08.012_bib4","series-title":"IBRANCE\u00ae capsules (palbociclib)","year":"2019"},{"issue":"1","key":"10.1016\/j.ejca.2022.08.012_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2022.08.012_bib6","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2022.08.012_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.08.012_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.08.011","article-title":"Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3","volume":"104","author":"Cristofanilli","year":"2018","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.08.012_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2022.08.012_bib10","first-page":"1","article-title":"Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study","volume":"5","author":"Im","year":"2019","journal-title":"J Glob Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.08.012_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-021-04263-9","article-title":"Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+\/HER2- advanced breast cancer in Chinese women","volume":"88","author":"Xu","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ejca.2022.08.012_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JGO.2016.008318","volume":"3","author":"Iwata","year":"2017","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.ejca.2022.08.012_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10147-018-1359-3","article-title":"Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients","volume":"24","author":"Masuda","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.08.012_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10147-018-1353-9","article-title":"Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients","volume":"24","author":"Mukai","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.08.012_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4048\/jbc.2021.24.e13","article-title":"Palbociclib plus fulvestrant in Korean patients from PALOMA-3 with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"24","author":"Kim","year":"2021","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.ejca.2022.08.012_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920963925","article-title":"MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase III study","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.08.012_bib17","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ejca.2022.08.012_bib18","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1634\/theoncologist.2019-0019","article-title":"Palbociclib with letrozole in postmenopausal women with ER+\/HER2- advanced breast cancer: hematologic safety analysis of the randomized PALOMA-2 trial","volume":"24","author":"Dieras","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejca.2022.08.012_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jnci\/djy109","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+\/HER2- advanced breast cancer","volume":"111","author":"Dieras","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ejca.2022.08.012_bib20","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1002\/onco.13684","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: updated analysis with up to 5 years of follow-up","volume":"26","author":"Finn","year":"2021","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ejca.2022.08.012_bib21","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in combination with fulvestrant in women with hormone receptor-positive\/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ejca.2022.08.012_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13058-020-01263-0","article-title":"Hematologic adverse events following\u00a0palbociclib dose reduction in patients with hormone\u00a0receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies","volume":"22","author":"Ettl","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2022.08.012_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-020-00771-5","article-title":"Impact of dose reduction on efficacy: implications of exposure-response analysis of palbociclib","volume":"16","author":"Zheng","year":"2021","journal-title":"Target Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.08.012_bib24","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1158\/1541-7786.MCR-17-0172","article-title":"CDK4\/6 inhibition on glucose and pancreatic beta cell homeostasis in young and aged rats","volume":"15","author":"Sacaan","year":"2017","journal-title":"Mol Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:51Z","timestamp":1760733531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922004890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":24,"alternative-id":["S0959804922004890"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.08.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer: Primary results from PALOMA-4","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}